Aker BioMarine

AKBM

NO0010886625

Fishing & Farming

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-15 am EDT			5-day change	1st Jan Change
65.7 ^NOK	-4.09%		-1.94%	+42.83%

Feb. 14	Aker BioMarine AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 14	Aker BioMarine AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aker Biomarine as Provides Earnings Outlook for the Year 2021 and 2022

December 30, 2021

Aker BioMarine AS provided earnings outlook for the year 2021 and 2022. For the 2021, the company expected annual sales to be somewhat below last year?s revenue of USD 289 million. For the 2022, the company targets revenue growth of 20%-25%.

Latest news about Aker BioMarine

Aker BioMarine AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Aker BioMarine AS Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Transcript : Aker BioMarine AS, Q4 2023 Earnings Call, Feb 14, 2024	Feb. 14
Aker BioMarine ASA Receives Purchase Order for Algae-Based Omega-3 Oils	Dec. 08	CI
Aker BioMarine Wins $6 Million Order for Omega-3 Oils; Production Capacity Expansion Planned	Dec. 08	MT
Aker BioMarine AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Transcript : Aker BioMarine AS, Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	23-10-24	MT
Aker Biomarine Begins Krill Oil Sales in South Korea	23-09-25	MT
Aker Biomarine Announces Successful Launch of Superba Krill Oil in South Korea	23-09-25	CI
Aker BioMarine's Krill Oil Brand Wins Australian Nod for Two Health Claims	23-08-25	MT
Aker BioMarine Gains Regulatory Approval for US Commercial Launch of Dietary Supplement	23-08-10	MT
Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US	23-08-09	CI
Aker BioMarine AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
Transcript : Aker BioMarine AS, Q2 2023 Earnings Call, Jul 14, 2023	23-07-14
Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023	23-07-13	CI
Aker BioMarine AS Announces Intention to Change Group Financial Reporting and Legal Entity Structure	23-06-29	CI
Aker BioMarine Spinoff, Microsoft Norway Team Up on Plastic Circularity	23-05-02	MT
Aker BioMarine AS Provides Sales Guidance for the Second Quarter of 2023	23-04-28	CI
Transcript : Aker BioMarine AS, Q1 2023 Earnings Call, Apr 28, 2023	23-04-28
Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-03-30	CI
Aker BioMarine AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Aker BioMarine AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil	22-12-21	CI
Aker BioMarine AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-01	CI

Chart Aker BioMarine

Duration

Period

More charts

Company Profile

Aker Biomarine ASA is a Norway-based biotech innovator and Antarctic krill-harvesting company. It consists of two business segments: Ingredients and Brands. Under The Ingredients segment, the Company develops krillbased ingredients for human applications in the nutraceutical and dietary supplement space, and animal feed applications for aquaculture and pet food. Under The Brands segment, the Company has two companies: Lang Pharma Nutrition and Epion Brands. Lang Pharma Nutrition is a full service, mass market private label and corporate brand manufacturer within supplements. Epion Brands has its own consumer brand in the US market, Kori, being on the shelves of retailers. Aker BioMarine's focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste.

Sector

Fishing & Farming

Calendar

2024-04-15 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Aker BioMarine

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.004 USD

Average target price

5.116 USD

Spread / Average Target

-14.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Fishing & Farming

	1st Jan change	Capi.
AKER BIOMARINE	+42.83%	526M
QL RESOURCES	+8.06%	3.14B
SLC AGRÍCOLA S.A.	-3.83%	1.54B
ROS AGRO PLC	-95.58%	1.61B
SILDARVINNSLAN HF.	-9.62%	1.24B
SHENZHEN KINGKEY SMART AGRICULTURE TIMES CO.,LTD	-5.79%	1.26B
GODREJ AGROVET LIMITED	-6.67%	1.19B
PT FAP AGRI TBK	0.00%	1.21B
CHERKIZOVO GROUP	-.--%	1.2B
FRESH DEL MONTE PRODUCE INC.	-5.03%	1.19B

Other Fishing & Farming

Aker BioMarine

Equities

AKBM

NO0010886625

Fishing & Farming

Aker Biomarine as Provides Earnings Outlook for the Year 2021 and 2022

EPS Revisions